Cartesian Therapeutics, Inc.

As of June 30, 2026, Cartesian Therapeutics, Inc. carries a market capitalization of 270.34M, placing it among publicly traded companies globally. Its enterprise value stands at 197.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cartesian Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Cartesian Therapeutics, Inc. has 30.04M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 188.55, and the price-to-book ratio stands at -2.47.

These figures are as of June 30, 2026. The EV/Sales ratio of 152.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 197.03M versus a market cap of 270.34M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cartesian Therapeutics, Inc. maintains a current ratio of 7.48, meaning it holds 7.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -50.99, indicating conservative leverage, while an interest coverage ratio of -184.68 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -42.94, reflecting losses generated across the asset base. The company generates approximately 17,770.70 in revenue per employee across its workforce of 72.75, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Cartesian Therapeutics, Inc.'s stock has declined approximately 25.64% over the past 52 weeks. The 50-day moving average sits at 7.07, while the 200-day moving average is 6.68.

Over the twelve months ended June 30, 2026, Cartesian Therapeutics, Inc. generated 1.29M in revenue and converted that into -132.95M in net income, yielding earnings per share of -4.89. EBITDA reached -137.73M, while operating income came in at -86.36M.

As of June 30, 2026, Cartesian Therapeutics, Inc. holds 129.20M in cash and equivalents against 55.89M in total debt, resulting in a net debt position of -82.94M. Total book value stands at -109.61M, with working capital of 116.47M providing operational flexibility.

Cartesian Therapeutics, Inc. produced -66.99M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.82M in capital expenditures, free cash flow totaled -68.81M - equivalent to -2.54 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -6,679.69 and net profit margin of -10,283.75 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -28.13: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -21.34, meaning Cartesian Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cartesian Therapeutics, Inc.'s most recent stock split took place on April 5, 2024 with a 30:1 split ratio.

As of June 30, 2026, Cartesian Therapeutics, Inc. has an Altman Z-Score of -7.22, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.